Trial Profile
Differentiation between benign and malignant pancreaticobiliary lesion by measuring the bile levels of porphyrins after oral administration of 5-aminolevulinic acid.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2021
Price :
$35
*
At a glance
- Drugs Aminolevulinic acid (Primary)
- Indications Biliary cancer; Pancreatic cancer
- Focus Therapeutic Use
- 15 Jun 2021 Status changed from not yet recruiting to completed.
- 11 Sep 2015 New trial record